DV
Dividend Vision

NXTC — NextCure  Inc

NextCure  Inc (NXTC)

Total return is -96.6% over the past 7.3 years, 298.0 points behind SPY at 201.4%. Its deepest 1-year drawdown was 88.8%.

NextCure is a clinical-stage biopharmaceutical company developing immunotherapy and targeted cancer treatments, including antibody-drug conjugates and immune checkpoint modulators, along with a candidate for Alzheimer's disease. The company does not currently distribute dividends. NextCure appeals to investors seeking exposure to early-stage biotech innovation rather than current income.

NXTC key facts

Asset type
Stock
Asset class
Equity
Inception date
05/09/2019
Last close
$8.21
Market cap
$19,505,318
Average volume
261800.0
Beta
1.421
Payout ratio
0.0
Forward P/E
0.0
EPS
$-15.50